X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (267) 267
Data Set (28) 28
Book Chapter (5) 5
Publication (4) 4
Conference Proceeding (2) 2
Patent (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (120) 120
index medicus (104) 104
melanoma (100) 100
female (87) 87
male (83) 83
middle aged (76) 76
oncology (71) 71
aged (69) 69
adult (63) 63
melanoma - pathology (56) 56
dermatology (49) 49
skin neoplasms - pathology (48) 48
metastasis (40) 40
cancer (39) 39
survival (39) 39
melanoma - drug therapy (37) 37
prognosis (30) 30
cutaneous melanoma (29) 29
melanoma - mortality (29) 29
treatment outcome (29) 29
skin neoplasms - drug therapy (28) 28
neoplasm staging (27) 27
metastases (26) 26
care and treatment (25) 25
ipilimumab (25) 25
metastatic melanoma (25) 25
immunotherapy (24) 24
retrospective studies (24) 24
skin cancer (24) 24
patients (23) 23
malignant-melanoma (22) 22
skin neoplasms - diagnosis (22) 22
skin neoplasms - mortality (22) 22
survival analysis (22) 22
aged, 80 and over (21) 21
melanoma - diagnosis (21) 21
analysis (20) 20
melanoma - secondary (20) 20
chemotherapy (19) 19
medicine & public health (19) 19
germany (18) 18
immunology (18) 18
medicine, research & experimental (18) 18
melanoma - therapy (18) 18
skin neoplasms - therapy (18) 18
therapy (16) 16
tumors (16) 16
young adult (16) 16
adolescent (15) 15
follow-up studies (15) 15
antineoplastic agents - therapeutic use (14) 14
research (14) 14
medical research (13) 13
melanoma - genetics (13) 13
neoplasm metastasis (13) 13
pembrolizumab (13) 13
american joint committee (12) 12
antineoplastic agents - administration & dosage (12) 12
nivolumab (12) 12
prognostic factors (12) 12
regression analysis (12) 12
sentinel lymph node biopsy (12) 12
diagnosis (11) 11
follow-up (11) 11
kaplan-meier estimate (11) 11
medical prognosis (11) 11
medicine (11) 11
patient outcomes (11) 11
proportional hazards models (11) 11
risk factors (11) 11
survival rate (11) 11
clinical trials (10) 10
malignant melanoma (10) 10
management (10) 10
melanoma - immunology (10) 10
melanoma - surgery (10) 10
multivariate analysis (10) 10
mutation (10) 10
skin neoplasms (10) 10
antineoplastic agents - adverse effects (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer research (9) 9
child (9) 9
germany - epidemiology (9) 9
lymphatic metastasis (9) 9
prospective studies (9) 9
registries (9) 9
skin (9) 9
time factors (9) 9
antibodies, monoclonal - therapeutic use (8) 8
biopsy (8) 8
development and progression (8) 8
hematology, oncology and palliative medicine (8) 8
high-risk melanoma (8) 8
medicine, experimental (8) 8
multidisciplinary sciences (8) 8
protein (8) 8
research article (8) 8
surgery (8) 8
abridged index medicus (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 210 - 225
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1403 - 1414
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 190 - 209
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e81624
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2908 - 2918
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 10/2015, Volume 13, Issue 10, pp. 1055 - 1056
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 77 - 89
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein... 
Vemurafenib | BRAF inhibitor | Melanoma | BRAF mutation
Journal Article
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 06/2018, Volume 89, Issue 6, pp. 559 - 565
BackgroundSensitive outcome measures for clinical trials on cerebellar ataxias are lacking. Most cerebellar ataxias progress very slowly and quantitative... 
SURGERY | PSYCHIATRY | FOLLOW-UP | COHORT | SCALE | SEVERITY | CLINICAL NEUROLOGY | DISEASE PROGRESSION | Consortia | Neurology | Clinical trials | Ataxia | Mutation | Patients | Variance analysis | Age
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 10/2015, Volume 13, Issue 10, pp. 1055 - 1056
Journal Article
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 10/2015, Volume 13, Issue 10, pp. 1055 - 1056
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Endocrine System - drug effects | Adult | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Kidney - drug effects | Antineoplastic Agents - immunology | Pancreas - drug effects | Gastrointestinal Tract - drug effects | Melanoma - pathology | CTLA-4 Antigen - immunology | Nervous System - drug effects | Melanoma - drug therapy | Respiratory System - drug effects | Aged | Skin - drug effects | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology
Journal Article